Insight Molecular Diagnostics Inc.

NASHVILLE, Tenn., July 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today highlighted a favorable new Medicare policy supporting expanded coverage for donor-derived cell-free DNA (dd-cfDNA) testing in transplant care.

globenewswire.com - 2026-07-16 15:22:00

Key member of management ranks at top 2% of researchers in the field of laboratory diagnostics and top 2.5% of all researchers worldwide, based on H-index of 58 Recent studies advanced science of molecular diagnostic testing for transplanted organ rejection, published in Clinical Chemistry, Transplant International, American Journal of Transplantation and Nephrology Dialysis Transplantation, among others NASHVILLE, Tenn., June 29, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that its Chief Science Officer, Prof.

globenewswire.com - 2026-06-29 08:00:00

-Grant Supports Health Economic Research Comparing In-House versus Send-Out dd-cfDNA Testing in Kidney Transplantation-

globenewswire.com - 2026-06-22 14:07:00

NASHVILLE, Tenn., June 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX) ("iMDx") today announced the online publication of a favorable article in Clinical Chemistry, the premier, peer-reviewed scientific publication of the Association for Diagnostics & Laboratory Medicine. The article highlights the concordant performance between iMDx's digital-PCR-based flagship transplant monitoring test, GraftAssure™, and a competing next-generation-sequencing-based assay kit that is sold outside of the U.S.

globenewswire.com - 2026-06-16 16:05:00

American Journal of Transplantation publishes public pre-proof showing novel CM-score superior to either fractional or absolute measurement of dd-cfDNA alone GraftAssure assay doubles reliability of positive results in screening cohort In for-cause testing of kidney transplant patients, the positive predictive value using the CM-Score increased to greater than 80% NASHVILLE, Tenn.

globenewswire.com - 2026-06-11 16:17:27

NASHVILLE, Tenn., June 11, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced an online published article in the American Journal of Transplantation asserting statistical superiority of the company's flagship GraftAssure transplant rejection monitoring assay.

globenewswire.com - 2026-06-11 16:17:00

Insight Molecular Diagnostics Inc. (IMDX) Shareholder/Analyst Call Prepared Remarks Transcript

seekingalpha.com - 2026-06-11 15:42:09

NASHVILLE, Tenn., June 09, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced it will be highlighting its GraftAssure™ technology at the upcoming American Transplant Congress, to be held in Boston from Saturday, June 20th through Wednesday, June 24th.

globenewswire.com - 2026-06-09 16:05:00

Insight Molecular Diagnostics Inc. (IMDX) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-13 20:30:45

Progressing toward commercialization with third-party head-to-head data publications and GALACTIC registry study engagement Northeast kidney transplant center (among the top 10 in the U.S.) is first to sign clinical trial agreement to participate in GALACTIC study Booked research-use-only purchase by E.U. transplant center and APAC purchase expected in coming days Anticipate significant U.S. orders to follow FDA marketing authorization Encouraging dialogue with FDA supports expected authorization later in 2026 NASHVILLE, Tenn.

globenewswire.com - 2026-05-13 16:05:00